Full Text View
Tabular View
No Study Results Posted
Related Studies
Immunogenicity and Safety of Pentaxim in South African Infants
This study has been completed.
Study NCT00254969   Information provided by Sanofi-Aventis
First Received: November 15, 2005   Last Updated: February 4, 2010   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
No publications provided by Sanofi-Aventis

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J. 2011 Nov 28;101(12):879-83.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services